Despite numerous efforts to identify reliable biomarkers, e.g. for tumour diagnosis only a limited number of biomarkers are currently used in the clinic, including alpha-fetoprotein, carcinoembryonic antigen (CEA), prostate-specific antigen or the cancer antigens 15-3, 19-9 and 125 12. Here, CEACAM5 is linked to neoplasm.